Tobacco Company Efforts to Influence the Food and Drug Administration-Commissioned Institute of Medicine Report An Analysis of Documents Released through Litigation

English version České info

Background:
Spurred by the creation of potential modified risk tobacco products, the US Food and Drug Administration (FDA) commissioned the Institute of Medicine (IOM) to assess the science base for tobacco “harm reduction,” leading to the 2001 IOM report Clearing the Smoke. The objective of this study was to determine how the tobacco industry organized to try to influence the IOM committee that prepared the report.

Methods and Findings:
We analyzed previously secret tobacco industry documents in the University of California, San Francisco Legacy Tobacco Documents Library, and IOM public access files. (A limitation of this method includes the fact that the tobacco companies have withheld some possibly relevant documents.) Tobacco companies considered the IOM report to have high-stakes regulatory implications. They developed and implemented strategies with consulting and legal firms to access the IOM proceedings. When the IOM study staff invited the companies to provide information on exposure and disease markers, clinical trial design for safety and efficacy, and implications for initiation and cessation, tobacco company lawyers, consultants, and in-house regulatory staff shaped presentations from company scientists. Although the available evidence does not permit drawing cause-and-effect conclusions, and the IOM may have come to the same conclusions without the influence of the tobacco industry, the companies were pleased with the final report, particularly the recommendations for a tiered claims system (with separate tiers for exposure and risk, which they believed would ease the process of qualifying for a claim) and license to sell products comparable to existing conventional cigarettes (“substantial equivalence”) without prior regulatory approval. Some principles from the IOM report, including elements of the substantial equivalence recommendation, appear in the 2009 Family Smoking Prevention and Tobacco Control Act.

Conclusions:
Tobacco companies strategically interacted with the IOM to win several favored scientific and regulatory recommendations.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Tobacco Company Efforts to Influence the Food and Drug Administration-Commissioned Institute of Medicine Report An Analysis of Documents Released through Litigation. PLoS Med 10(5): e32767. doi:10.1371/journal.pmed.1001450
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001450

Souhrn

Conclusions:
Tobacco companies strategically interacted with the IOM to win several favored scientific and regulatory recommendations.

Please see later in the article for the Editors' Summary

Zdroje

1. Glantz S, Slade J, Bero LA, Hanauer P, Barnes DE (1996) The Cigarette Papers. Berkeley and Los Angeles, California: University of California Press.

2. National Cancer Institute (2001) Monograph 13: Risks Associated with Smoking Cigarettes with Low Tar Machine-Measured Yields of Tar and Nicotine. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute.

3. Stratton K, Shetty P, Wallace R, Bondurant S (2001) Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, D.C.: National Academy Press.

4. (2006) United States of America, et al. v. Philip Morris USA Inc., et al, 449 F. Supp 2d 1 (D.C. D. C. 2006), aff'd as to the tobacco companies except for certain remedies, 566 F.3d 1095 (D.C. Cir. 2009), cert. den. 130 S. Ct. 3501 (June 28, 2010) (also vacating judgment against the Tobacco Institute and Center for Tobacco Research as moot because the organizations “no longer exist”).

5. Proctor R (2011) Golden Holocaust: Origins of the Cigarette Catastrophe and the Case for Abolition. Berkeley and Los Angeles, CA: University of California Press.

6. Parker-Pope T. Safer Cigarettes: A History. Nova Oct. 2, 2001 http://www.pbs.org/wgbh/nova/body/safer-cigarettes-history.html. (Accessed Nov. 3, 2012)

7. The National Academies: Who We Are. http://www.nas.edu/about/whoweare/index.html. (Accessed October 22, 2012)

8. The National Academies: Our Reputation. http://www.nationalacademies.org/about/reputation/index.html. (Accessed October 22, 2012)

9. BatesC (2001) Clearing the smoke or muddying the water? Tob Control 10: 87–88.

10. HongMK, BeroLA (2002) How the tobacco industry responded to an influential study of the health effects of secondhand smoke. BMJ 325: 1413–1416.

11. OngEK, GlantzSA (2000) Tobacco industry efforts subverting International Agency for Research on Cancer's second-hand smoke study. Lancet 355: 1253–1259.

12. BeroLA (2005) Tobacco industry manipulation of research. Public Health Rep 120: 200–208.

13. OngEK, GlantzSA (2001) Constructing “sound science” and “good epidemiology”: tobacco, lawyers, and public relations firms. Am J Public Health 91: 1749–1757.

14. BabaA, CookDM, McGarityTO, BeroLA (2005) Legislating “sound science”: the role of the tobacco industry. Am J Public Health 95 Suppl 1: S20–27.

15. CookDM, TongEK, GlantzSA, BeroLA (2005) The power of paperwork: how Philip Morris neutralized the medical code for secondhand smoke. Health Aff (Millwood) 24: 994–1004.

16. MaloneRE, BalbachED (2000) Tobacco industry documents: treasure trove or quagmire? Tob Control 9: 334–338.

17. McDanielPA, MaloneRE (2005) Understanding Philip Morris's pursuit of US government regulation of tobacco. Tob Control 14: 193–200.

18. Philip Morris. Potential for Worldwide Product Regulation. 03 Sep 1999. Available: http://legacy.library.ucsf.edu/tid/yky97d00.

19. Philip Morris. Reducing Exposure to Harmful Substances in Tobacco: The Science Base. Oct 1999. Available: http://legacy.library.ucsf.edu/tid/gul90b00.

20. Philip Morris. Worldwide Regulatory Affairs Five Year Plan 1995–1999 ETS Strategy. Mar 1995. Available: http://legacy.library.ucsf.edu/tid/lrc74a00.

21. Levine A, Richman J. Arnold & Porter. Institute of Medicine Study on “Reducing Exposure to Harmful Substances in Tobacco: The Science Base”. 15 Nov 1999. Available: http://legacy.library.ucsf.edu/tid/syf42c00.

22. Multinational Business Services. Information Sharing with the IOM Committee on “Reducing Exposure to Harmful Substances in Tobacco”. 01 Oct 1999. Available: http://legacy.library.ucsf.edu/tid/fje25c00.

23. DiethelmPA, RielleJC, McKeeM (2005) The whole truth and nothing but the truth? The research that Philip Morris did not want you to see. Lancet 366: 86–92.

24. Geffe J. Philip Morris Research Laboratories GmbH. New Company Name. 26 Nov 2002. Available: http://legacy.library.ucsf.edu/tid/rzq34a00.

25. McAlpin L. Philip Morris. Institute of Medicine. 29 Nov 1999. Available: http://legacy.library.ucsf.edu/tid/kzj50b00.

26. Carchman R. Philip Morris. Given the project scope and its membership I have the following preliminary comments. Dec 1999. Available: http://legacy.library.ucsf.edu/tid/fcl70b00.

27. Hough JD. Philip Morris. Institute of Medicine. 01 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/itg70b00.

28. Patskan GJ. Philip Morris. IOM. 01 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/mok19c00.

29. Davies B. Philip Morris. Comments on IOM Document. Dec 1999. Available: http://legacy.library.ucsf.edu/tid/otm11b00.

30. Rickert WS (1996) Report of Canada's Expert Committee on Cigarette Modifications. Toronto, Ontario, Canada: Health Canada.

31. Rickert WS (1998) Report of Canada's Expert Committee on Cigarette Toxicity Reduction. Toronto, Ontario, Canada: Health Canada.

32. Cox RH, Rickert WS. Agreement for Independent Contractor Services between Labstat International Inc. and Philip Morris Incorporated. 15 Sep 2000. Available: http://legacy.library.ucsf.edu/tid/zrd34a00.

33. BarnesRL, HammondSK, GlantzSA (2006) The tobacco industry's role in the 16 Cities Study of secondhand tobacco smoke: do the data support the stated conclusions? Environ Health Perspect 114: 1890–1897.

34. Tobacco Documents Online Profiles: Jenkins, Roger Allen, Ph.D. http://tobaccodocuments.org/profiles/jenkins_roger.html. (Accessed April 12, 2012)

35. Tozzi J. Multinational Business Services. Data Sharing with the IOM Committee. 06 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/wpg95c00.

36. Solana RP. Philip Morris. You have posted invitation for public comment on the committee for “Assessing the Science Base for Tobacco Harm Reduction”. 12 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/vyd69h00.

37. Arnold & Porter. Profile of Dorothy Hatsukami. 21 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/qxl34a00.

38. Arnold & Porter. Profile of Garrett A. Fitzgerald. Dec 1999. Available: http://legacy.library.ucsf.edu/tid/dhz95c00.

39. Bondurant Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/xjl66c00.

40. Crout Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/odd92g00.

41. Fitzgerald Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/rdd92g00.

42. Gazdar Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/lhm80g00.

43. Giovino Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/wdd92g00.

44. Henderson Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/ded92g00.

45. Reuter Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/jed92g00.

46. Riley Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/ned92g00.

47. Shields Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/qvd92g00.

48. Wallace Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/hwd92g00.

49. Willerson Bibliography (in Philip Morris Collection). Dec 1999. Available: http://legacy.library.ucsf.edu/tid/jwd92g00.

50. Philip Morris. Stuart Bondurant (Confidential Document). 1996. Available: http://legacy.library.ucsf.edu/tid/yoy31h00.

51. John Richard Crout Resume (in Phlilip Morris Collection). 1998. Available: http://legacy.library.ucsf.edu/tid/tnq81g00.

52. Garret Adare Fitzgerald Resume (in Philip Morris Collection). 1998. Available: http://legacy.library.ucsf.edu/tid/zoy31h00.

53. Henderson Rogene F. PhD Dabt 1998 Resume (in Philip Morris Collection). 01 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/woy31h00.

54. Rogene Faulkner-Henderson Resume (in Philip Morris Collection). 00 1998. Available: http://legacy.library.ucsf.edu/tid/xoy31h00.

55. Barbara Hulka, MD Resume (in Philip Morris collection). 01 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/xnq81g00.

56. Barbara Sorenson Hulka Resume (in Philip Morris Collection). 1998. Available: http://legacy.library.ucsf.edu/tid/mbz70g00.

57. David J. Riley, M.D Resume (in Philip Morris collection). 01 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/ybc79h00.

58. Dr. Peter Reuter, Ph.D Resume (in Philip Morris collection). 01 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/zbc79h00.

59. Adi F. Gazdar, MD Resume (in Philip Morris collection). 01 Dec 1999. Available: http://legacy.library.ucsf.edu/tid/elc79h00.

60. Stratton K. Institute of Medicine. Re: “Assessing the Science Base for Tobacco Harm Reduction” Meetings (email to Rick Solana). 13 Jan 2000. Available: http://legacy.library.ucsf.edu/tid/aha49c00.

61. Solana RP. Fw: Re: “Assessing the Science Base for Tobacco Harm Reduction” Meetings. 13 Jan 2000. Available: http://legacy.library.ucsf.edu/tid/zga49c00.

62. Stratton K. The Institute of Medicine Has Convened the Committee to Assess the Science Base for Tobacco Harm Reduction in Response to a Request by the Food and Drug Administration. 28 Jan 2000. Available: http://legacy.library.ucsf.edu/tid/erg95c00.

63. Stratton K. The Institute of Medicine Has Convened the Committee to Assess the Science Base for Tobacco Harm Reduction in Response to a Request by the Food and Drug Administration. 28 Jan 2000. Available: http://legacy.library.ucsf.edu/tid/keg70d00.

64. Stratton K. Letter from Kathleen Stratton to Rufus H Honeycutt regarding harmful substances in tobacco. 01 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/jvy92a99.

65. Solana RP. I look forward to meeting you on March 1. 02 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/epg80b00.

66. Gorrod JW, Jacob III P, editors(1999) Analytical Determination of Nicotine and Related Compound and their Metabolites. Amsterdam, The Netherlands: Elsevier Science B.V.

67. HongMK, BeroLA (2006) Tobacco industry sponsorship of a book and conflict of interest. Addiction 101: 1202–1211.

68. Philip Morris. CVs of Presenters Scheduled for 3-2001 Presentation. 24 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/tiw50b00.

69. Philip Morris. Prep Sessions. Mar 2000. Available: http://legacy.library.ucsf.edu/tid/xra49c00.

70. McAlpin L. IOM Information. 11 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/hkn47c00.

71. King V. Philip Morris Worldwide Scientific Affairs. Facsimile transmitting draft of Don Leydens' presentation. 29 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/ivk45c00.

72. Philip Morris. Draft materials for IOM presentations. Mar 2000. Available: http://legacy.library.ucsf.edu/tid/evk45c00.

73. Philip Morris. How Does the Uptake of Gas Phase and Particulate Phase Smoke Constituents Relate to Cigarette Design? The Total Exposure Project. 17 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/nlm92g00.

74. Philip Morris. Low Yield Cigarettes 01 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/kvk45c00.

75. YanoE (2005) Japanese spousal smoking study revisited: how a tobacco industry funded paper reached erroneous conclusions. Tob Control 14: 227–233; discussion 233–225.

76. ChapmanS (2005) Research from tobacco industry affiliated authors: need for particular vigilance. Tob Control 14: 217–219.

77. Sourcewatch: Peter N. Lee. http://www.sourcewatch.org/index.php?title=Peter_N._Lee. (Accessed April 19, 2012)

78. Wertz M, Kyriss T, Paranjape S, Glantz SA. Response to Comments from Michael J. Oldham Ph.D., Associate Principal Scientist, and Willie J. McKinney Jr., Ph.D., D.A.B.T., Director, Product Integrity, Altria Client Services, March 5, 2012, re: Wertz et al. 2011 “The Toxic Effects of Cigarette Additives. Philip Morris' Project Mix Reconsidered: An Analysis of Documents Released through Litigation”, PLoS Medicine, December 2011, Vol 8(12). http://www.plosmedicine.org/annotation/listThread.action?root=13441. (Accessed Apr. 24, 2012)

79. Baker R. Fax to Dr. Scott Appleton Re: Peter Lee. 16 Jun 2000. Available: http://legacy.library.ucsf.edu/tid/gcz92a99.

80. Lee PN. Letter submitting “Lung cancer and type of cigarette smoked” to BMJ. 03 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/quk45c00.

81. Sanders E. Re: Peter Lee Manuscript for IOM. 10 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/muk45c00.

82. LeePN (2001) Lung cancer and type of cigarette smoked. Inhal Toxicol 13: 951–976.

83. Gardner DE, Inhalation Toxicology. THANK YOU FOR THE REVISION OF YOUR MANUSCRIPT NUMBER 0-01-571 ENTITLED “LUNG CANCER AND TYPE OF CIGARETTE SMOKED”. 14 May 2001. Available: http://legacy.library.ucsf.edu/tid/ijg50d00.

84. Gardner DE. Donald E. Gardner, Ph.D., Fellow: Ats. Inhalation Toxicology Associates, Inc. Consultants. 00 1999. Available: http://legacy.library.ucsf.edu/tid/yob90d00.

85. Burger GT, Lyalls TM. Accounts Payable Voucher. Dr. Gardner Provided Professional Consulting Services to R.J. Reynolds Tobacco at the Request of Dr. Gary T. Burger from January 17 through February 4, 2000 (20000117–20000204). 15 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/iod50b00.

86. Burger GT, Lyalls TM. Accounts Payable Voucher. At the Request of R.J. Reynolds Tobacco, Dr. Gardner Attended an Eclipse Expert Panel Meeting in Philadelphia on March 23 and 24, 2000 (20000323–20000324). 31 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/jod50b00.

87. Burger GT, Lyalls TM. Accounts Payable Voucher. Dr Gardner Was Invited by R.J. Reynolds Tobacco to Participate on an Expert Panel to Review Research on Eclipse. 26 Feb 1999. Available: http://legacy.library.ucsf.edu/tid/hod50b00.

88. Burger GT, Lyalls TM. Accounts Payable Voucher. Honorarium—Dr. Donald E. Gardner Served on an Expert Panel to Review Research on Eclipse at the Invitation of R.J. Reynolds Tobacco. 26 Feb 1999. Available: http://legacy.library.ucsf.edu/tid/god50b00.

89. Gardner DE, Burger GT. Enclosed for Your Review and Approval Is an Invoice for Consultant Service on Eclipse Carbon Monoxide Study Group That Met in Winston-Salem, North Carolina. 13 Nov 1996. Available: http://legacy.library.ucsf.edu/tid/eod50b00.

90. Townsend DE, Lyalls TM. Accounts Payable Voucher. At the Request of R.J. Reynolds Tobacco, Dr. Gardner Attended an Eclipse Expert Panel Meeting in San Francisco, CA on March 30 & 31, 2001 (20010330–20010331). 11 Apr 2001. Available: http://legacy.library.ucsf.edu/tid/end50b00.

91. Coggins C. Ms 01-571: Lung Cancer and Type of Cigarette Smoked. Lee, P.N. 30 Mar 2001. Available: http://legacy.library.ucsf.edu/tid/ync43c00.

92. Patskan GJ. Re: Your IOM Presentation. 14 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/bsa49c00.

93. WertzMS, KyrissT, ParanjapeS, GlantzSA (2011) The toxic effects of cigarette additives. Philip Morris' project mix reconsidered: an analysis of documents released through litigation. PLoS Med 8: e1001145.

94. Reynolds Tobacco R.J. (2000) A Scientific Strategy for Assessing Tobacco Product Harm Reduction Potential. Presentation to the IOM Industry Working Group to Assess the Science Base for Tobacco Harm Reduction. Washington, D.C. IOM Public Access File.

95. Rucker TJ. Attached is a Page from a Briefing Paper Draft by Seth Moskowitz to be Given to Dave, Brice, Etc., for Media Training Next Week. 17 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/drq31d00.

96. Moskowitz SW. Regulation/Policy. 13 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/erq31d00.

97. Philip Morris Tobacco (2000) Presentation to the IOM Industry Working Group to Assess the Science Base for Tobacco Harm Reduction. Washington, D.C. IOM Public Access File.

98. Brown & Williamson Tobacco (2000) Assessment Strategies for Reduced Risk Cigarettes. Presentation to the IOM Industry Working Group to Assess the Science Base for Tobacco Harm Reduction. Washington, D.C. IOM Public Access File.

99. Solana RP. IOM Meeting - FYI. 02 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/sre95c00.

100. Solana R. On March 1, the following Philip Morris scientists and I participated in a meeting with an Institute of Medicine working group of the Committee to Assess the Science Base for Tobacco Harm Reduction. Apr 2000. Available: http://legacy.library.ucsf.edu/tid/spg95c00.

101. Philip Morris. Our Understanding of IOM Committee Task. 01 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/upg95c00.

102. Stratton K. Letter to RP Solana (Philip Morris) with follow-up questions from the Institute of Medicine Committee to Assess the Science Base for Harm Reduction from Tobacco. 17 Apr 2000. Available: http://legacy.library.ucsf.edu/tid/jmv95c00.

103. Stratton K. Letter to JD DeBethizy (RJR) regarding follow-up questions from the Institute of Medicine Committee to Access the Science Base for Harm Reduction from Tobacco. 17 Apr 2000. Available: http://legacy.library.ucsf.edu/tid/qrs81b00.

104. Stratton K. Letter to C Coggins (Lorrilard) transmititng follow-up questions from the Institute of Medicine Committee to Access the Science Base for Harm Reduction from Tobacco. 17 Apr 2000. Available: http://legacy.library.ucsf.edu/tid/sau64d00.

105. Stratton K. Letter from Kathleen Stratton to Scott Appleton (Brown and Williamson) regarding questions from the Institute of Medicine Committee. 17 Apr 2000. Available: http://legacy.library.ucsf.edu/tid/bsa14a99.

106. Philip Morris. Draft responses to IOM questions. 2000. Available: http://legacy.library.ucsf.edu/tid/ney08c00.

107. Bugg JJ, Osborne KB. IOM - Reread. 05 May 2000. Available: http://legacy.library.ucsf.edu/tid/vnv46c00.

108. Osborne K. Re: IOM - Reread. 07 May 2000. Available: http://legacy.library.ucsf.edu/tid/xnv46c00.

109. Philip Morris. Privileged+Confidential KBO Comments to draft responses to IOM questions. May 2000. Available: http://legacy.library.ucsf.edu/tid/sey08c00.

110. Bugg JJ. Q 10 Rewrite. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/pey08c00.

111. Solana R (2000) “In response to your follow-up question date April 17…”. Washington, D.C. IOM Public Access File.

112. WSA Scientific Review of the 2001 IOM Report “Clearing the Smoke”. 09 Apr 2001. Available: http://legacy.library.ucsf.edu/tid/guz81c00.

113. Lau RW. Re: Rick's Questions. 18 Mar 2001. Available: http://legacy.library.ucsf.edu/tid/ynk92c00.

114. Philip Morris. Harm Reduction Evaluation Process Process for Reduced-Harm Product Use and Claims. 13 Oct 2000. Available: http://legacy.library.ucsf.edu/tid/frv46c00.

115. Slade J (2000) Filtered & Light Cigarettes. Presentation to the IOM Committee to Assess the Science Base for Tobacco Harm Reduction: March 2, 2000–March 3, 2000. Washington, DC: IOM Public Access File.

116. Slade J (2000) Letter from John Slade to the Committee with supporting materials. Mar. 29, 2000. Washington, DC: IOM Public Access File.

117. Slade J (2000) Letter from John Slade to the Committee with supporting materials. May 8, 2000. Washington, DC: IOM Public Access File.

118. Slade J (2000) Letter from John Slade to the Committee. Aug. 13, 2000. Washington, DC: IOM Public Access File.

119. HirschhornN, BialousSA, ShatensteinS (2006) The Philip Morris External Research Program: results from the first round of projects. Tob Control 15: 267–269.

120. HirschhornN, BialousSA, ShatensteinS (2001) Philip Morris' new scientific initiative: an analysis. Tob Control 10: 247–252.

121. Letter from Adi F. Gazdar M.D re: preliminary application for research support, entitled “A comparison of bronchial epithelial changes in smokers and nonsmokers”. 14 Jan 1993. Available: http://legacy.library.ucsf.edu/tid/hhq72b00.

122. McAllister H. Council for Tobacco Research. Letter to A Gazdar regarding recent inquiry concerning support by Council for Tobacco Research. 22 Feb 1993. Available: http://legacy.library.ucsf.edu/tid/ihq72b00.

123. Research CfT. Request for peer review of New Application No. 3950 Adi F. Gazdar, Ph.D., University of Texas, Dallas, Texas Genes Involved in Lung Cancer Progression and Metastasis. 17 Jan 1994. Available: http://legacy.library.ucsf.edu/tid/zdg06d00.

124. Pierce. Council for Tobacco Research. Review of “Genes Involved in Lung Cancer Progression and Metastasis”. Available: http://legacy.library.ucsf.edu/tid/yrf06d00.

125. Lynch HT. Council for Tobacco Research. Review of ADI F. GAZDAR, M.D. #3950 “Genes Involved in Lung Cancer Progression and Metastasis”. 17 Feb 1994. Available: http://legacy.library.ucsf.edu/tid/zrf06d00.

126. Glenn J. Council for Tobacco Research. Letter to A. Gadzar declining funding of Application No. 3950. 25 Apr 1994. Available: http://legacy.library.ucsf.edu/tid/ctf06d00.

127. Gill GN. CTR Grant 3514 Nicotine Receptors in Human Lung Cancer. 24 Aug 1992. Available: http://legacy.library.ucsf.edu/tid/auf00d00.

128. Adams P, Minna J. Competing Renewal Application Genetic Lesions in Lung Cancer. 31 May 1996. Available: http://legacy.library.ucsf.edu/tid/xbo98d00.

129. Biographical Sketch Adi F. Gazdar, M.D. 11 Dec 1995. Available: http://legacy.library.ucsf.edu/tid/bco98d00.

130. Vogt P. Council for Tobacco Research. Review of Grant Application Grant Application #: 3514a. Available: http://legacy.library.ucsf.edu/tid/vbo98d00.

131. Joklik WK. Council for Tobacco Research. Review of “John D. Minna Genetic Lesions in Lung Cancer”. Available: http://legacy.library.ucsf.edu/tid/ubo98d00.

132. Glenn J. Council for Tobacco Research. Letter to JD Minna declining funding for Application No. 3514a. 17 Oct 1996. Available: http://legacy.library.ucsf.edu/tid/tbo98d00.

133. Wildenthal K. Letter to AF Gadzar explaining decision to decline approval to submit grant to PMERP. 15 Nov 2000. Available: http://legacy.library.ucsf.edu/tid/qwj20i00.

134. WSA Contracts. 17 Sep 2002. Available: http://legacy.library.ucsf.edu/tid/yop20i00.

135. Sourcewatch: Adi F. Gazdar. http://www.sourcewatch.org/index.php?title=Adi_F._Gazdar. (Accessed April 20, 2012)

136. Solana RP. Request for Applications 2003 Research Focus. Philip Morris External Research Program. 2003. Available: http://legacy.library.ucsf.edu/tid/gcs80g00.

137. Regulatory Circuitry. Philip Morris External Research Program Symposium 20071209–20071211. 09 Dec 2007. Available: http://legacy.library.ucsf.edu/tid/vos94g00.

138. Henderson R, IRRI. Symposium at SOT. 22 Mar 2001. Available: http://legacy.library.ucsf.edu/tid/xso20d00.

139. Walk RA. Fw: Walk, Letter to D. Hatsukami, 2003-10-30. 15 Apr 2005. Available: http://legacy.library.ucsf.edu/tid/zmt81g00.

140. Bondurant S. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction Opening Statement. 22 Feb 2001. Available: http://legacy.library.ucsf.edu/tid/lif31c00.

141. Solana RP. IOM. 22 Feb 2001. Available: http://legacy.library.ucsf.edu/tid/mif31c00.

142. Merlo E. Re: IOM. 22 Feb 2001. Available: http://legacy.library.ucsf.edu/tid/nif31c00.

143. Pfeil ME. Re: IOM. 22 Feb 2001. Available: http://legacy.library.ucsf.edu/tid/oif31c00.

144. Merlo E. Re: IOM. 22 Feb 2001. Available: http://legacy.library.ucsf.edu/tid/qif31c00.

145. Scruggs J. Re: President's Commission - Preliminary Draft Comments. 23 Feb 2001. Available: http://legacy.library.ucsf.edu/tid/dhf31c00.

146. Berlind M. IOM's 11 Principles. 25 Feb 2001. Available: http://legacy.library.ucsf.edu/tid/xtz81c00.

147. Desel P. Re: IOM's 11 Principles. 13 Mar 2001. Available: http://legacy.library.ucsf.edu/tid/ztz81c00.

148. Desel P. Email from Philip Morris in-House Counsel to Philip Morris in-House Counsel Memorializing a Discussion with Philip Morris Outside Litigation Counsel (Conley) Regarding Responding to the Institute of Medicine's Report on the Eleven Tobacco Regulatory Principles. 27 Mar 2001. Available: http://legacy.library.ucsf.edu/tid/ofv42b00.

149. Osborne K. IOM Report - Initial Observation. 23 Mar 2001. Available: http://legacy.library.ucsf.edu/tid/orz30i00.

150. Philip Morris USA and Philip Morris International Perspective on the Institute of Medicine's Eleven Regulatory Principles. 25 Feb 2001. Available: http://legacy.library.ucsf.edu/tid/fqh77a00.

151. Philip Morris USA and Philip Morris International Perspective on the Institute of Medicine's Eleven Regulatory Principles. 04 Apr 2001. Available: http://legacy.library.ucsf.edu/tid/kxd51b00.

152. Philip Morris USA and Philip Morris International Perspective on the Institute of Medicine's Eleven Regulatory Principles. 23 Apr 2001. Available: http://legacy.library.ucsf.edu/tid/jxd51b00.

153. Bugg JJ. RE: IOM Report - initial observation. 28 Mar 2001. Available: http://legacy.library.ucsf.edu/tid/kyw95g00.

154. Desel P. Fw: Draft WSA Review of IOM Report. 03 Apr 2001. Available: http://legacy.library.ucsf.edu/tid/uiy08c00.

155. McDanielPA, SmithEA, MaloneRE (2006) Philip Morris's Project Sunrise: weakening tobacco control by working with it. Tob Control 15: 215–223.

156. Burger GT (2000) “We at the R.J. Reynolds Tobacco Company appreciate the opportunity to respond…”. Washington DC: IOM Public Access File.

157. Wells J. Confidential Handwritten Notes of B&W in-House Counsel Reflecting Counsel's Legal Advice Regarding B&W's Draft Comment to National Academy of Sciences Institute of Medicine Concerning Assessment Strategies for Reduced Risk Cigarettes. 01 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/sse51i00.

158. Assessment Strategies for Reduced Risk Cigarettes; Comments by Brown & Williamson Tobacco Corporation; Presented to National Academy of Sciences Institute of Medicine Committee to Assess the Science Base for Tobacco Harm Reduction. 01 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/xti21c00.

159. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes (Confidential). 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/nyu06h00.

160. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/nxx43h00.

161. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 05 May 2000. Available: http://legacy.library.ucsf.edu/tid/snt56h00.

162. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 29 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/kao53h00.

163. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 05 May 2000. Available: http://legacy.library.ucsf.edu/tid/smt56h00.

164. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/tnx43h00.

165. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 27 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/ysv95h00.

166. Debethizy JD. Overview of Scientific Strategy. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 16 Mar 2000. Available: http://legacy.library.ucsf.edu/tid/sae34h00.

167. Debethizy JD. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 28 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/qdv95h00.

168. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 07 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/fzc93h00.

169. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 00 1999. Available: http://legacy.library.ucsf.edu/tid/krj94h00.

170. Debethizy JD, Doolittle DJ, Mosberg AT, Robinson JH. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/wzw45h00.

171. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/dlq05h00.

172. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 10 May 2000. Available: http://legacy.library.ucsf.edu/tid/gkf47h00.

173. Archived Email 1994–2000 (Box 11); an Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 28 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/ysi01i00.

174. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 05 May 2000. Available: http://legacy.library.ucsf.edu/tid/axw45h00.

175. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/yzx43h00.

176. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 05 May 2000. Available: http://legacy.library.ucsf.edu/tid/zio53h00.

177. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/sox43h00.

178. Debethizy JD, Borgerding MF, Doolittle DJ, Mosberg AT. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 09 May 2000. Available: http://legacy.library.ucsf.edu/tid/akf47h00.

179. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 01 May 2000. Available: http://legacy.library.ucsf.edu/tid/gvg16h00.

180. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/lgk72h00.

181. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 27 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/ulq43h00.

182. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/okf47h00.

183. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/ktp15h00.

184. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/ekf47h00.

185. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 04 May 2000. Available: http://legacy.library.ucsf.edu/tid/bcy43h00.

186. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 1993. Available: http://legacy.library.ucsf.edu/tid/fga82h00.

187. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 27 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/vmq43h00.

188. An Effective Scientific Strategy for Assessing Harm Reduction Potential in Cigarettes. 16 Mar 2006. Available: http://legacy.library.ucsf.edu/tid/xyk36h00.

189. IOM Science Base for Tobacco Harm Reduction. Mar 2001. Available: http://legacy.library.ucsf.edu/tid/ylx41h00.

190. TES_exposure_characterization _Leyden_D 1 ._to_IOM_(Presentation)_2000-03-01.ppt ExcelWorkbook.xls. Available: http://legacy.library.ucsf.edu/tid/fzl32h00.

191. Surrogate_markers_suitable_for_testing _Haussmann_H 1 ._to_IOM_Committee_(Presentation)_2000-03-01.ppt ExcelWorkbook.xls. Available: http://legacy.library.ucsf.edu/tid/gau32h00.

192. Epidemiology_of_low_tar_products _Sanders_E 1 ._to_IOM_Committee_(Presentation)_2000-03-01.ppt. 29 Feb 2000. Available: http://legacy.library.ucsf.edu/tid/kpl32h00.

193. Frame work presentation IOM principles draft 3-6.ppt∧PowerPointPresentation.ppt. 12 Feb 2002. Available: http://legacy.library.ucsf.edu/tid/paa42h00.

194. Eubanks S, Glantz S (2012) Bad Acts: The Racketeering Case Against the Tobacco Industry. Washington, D.C.: American Public Health Association Press.

195. Project Description: Evaluating the Scientific Evidence for Potential Reduced-Risk Tobacco Products (“Reduced Risk Review”). LSRO http://www.lsro.org/rrrvw/rrrvw_project_description.pdf. (Accessed April 20, 2012)

196. SchickSF, GlantzSA (2007) Old ways, new means: tobacco industry funding of academic and private sector scientists since the Master Settlement Agreement. Tob Control 16: 157–164.

197. Carmines EL. Fw: LSRO for Reduced Harm. 30 Nov 2004. Available: http://legacy.library.ucsf.edu/tid/noi91g00.

198. Brownawell AM (2007) The LSRO Report on Biological Effects Assessment in the Evaluation of Potential Reduced-Risk Tobacco Products. Bethesda, MA: Life Sciences Research Office.

199. Hilaire CLS (2007) The LSRO Report on Scientific Methods to Evaluate Potential Reduced-Risk Tobacco Products. Bethesda, MA: Life Sciences Research Office.

200. Lewis KD (2007) The LSRO Report on Exposure Assessment in the Evaluation of Potential Reduced-Risk Tobacco Products. Bethesda, MA: Life Sciences Research Office.

201. Lewis KD (2008) The LSRO Report on Differentiating the Health Risks of Categories of Tobacco Products. Bethesda, MA: Life Sciences Research Office.

202. PM Ongoing (and Completed) Legislative and Regulatory Projects for 20010000. 26 Apr 2001. Available: http://legacy.library.ucsf.edu/tid/arm10c00.

203. FDA Tobacco Jurisdiction Legislation in the 107th Congress House Bills. 20 Jun 2001. Available: http://legacy.library.ucsf.edu/tid/tth77a00.

204. FDA Tobacco Jurisdiction Legislation in the 107th Congress Side-by-Side Analysis. 19 Mar 2001. Available: http://legacy.library.ucsf.edu/tid/olz41b00.

205. Reduced-Risk Tobacco Products: Full Disclosure vs. Government Suppression of Truthful and Non-Misleading Information. Feb 2000. Available: http://legacy.library.ucsf.edu/tid/crx12c00.

206. Myers ML, Wheeler MC, Seffrin JR, Garrison JR. Letter to Congress States Bill “Would Do More to Protect the Tobacco Industry than to Protect the Public Health”. June 25, 2001 http://www.tobaccofreekids.org/press_releases/post/id_0372. (Accessed February 25)

207. S. 982–111th Congress: Family Smoking Prevention and Tobacco Control Act. (2009). In GovTrack.us (database of federal legislation). Retrieved June 19, 2012, from http://www.govtrack.us/congress/bills/111/s982.

208. U.S. Food and Drug Administration. Overview Questions: Substantial Equivalence. http://www.fda.gov/TobaccoProducts/ResourcesforYou/ForIndustry/ucm237528.htm. (Accessed Nov. 5, 2012)

209. (2012) Letter to Gregory N. Connolly, Harvard School of Public Health. June 22, 2012.: US Food and Drug Administration Freedom of Information Office.

210. BarnoyaJ, GlantzS (2002) Tobacco industry success in preventing regulation of secondhand smoke in Latin America: the “Latin Project”. Tob Control 11: 305–314.

211. BarnoyaJ, GlantzSA (2006) The tobacco industry's worldwide ETS consultants project: European and Asian components. Eur J Public Health 16: 69–77.

212. LandmanA, CorteseDK, GlantzS (2008) Tobacco industry sociological programs to influence public beliefs about smoking. Soc Sci Med 66: 970–981.

213. World Health Organization (2003) WHO Framework Convention on Tobacco Control. Geneva, Switzerland.

214. IOM (Institute of Medicine) (2012) Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC.

215. GlantzSA, BarnesR, EubanksSY (2009) Compromise or capitulation? US Food and Drug Administration jurisdiction over tobacco products. PLoS Med 6: e1000118.

216. World Health Organization. Guidelines for implementation of Article 5.3 of the WHO Framework Convention on Tobacco Control. http://www.who.int/fctc/guidelines/article_5_3.pdf. (Accessed 20 Feb 2013)

217. LeeYO, GlantzSA (2011) Menthol: putting the pieces together. Tob Control 20 Suppl 2: ii1–7.

218. MejiaAB, LingPM, GlantzSA (2010) Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA. Tob Control 19: 297–305.

219. Philip Morris. Fig 1-Reduced_Risk Product Usage 41.Ppt. 20 Jan 2004. Available: http://legacy.library.ucsf.edu/tid/zie30i00.